ProSTEM Receives Sharia Compliance Recommendation from LPPOM MUI

ProSTEM Receives Sharia Compliance Recommendation from LPPOM MUI. The development of stem cell-based therapies in Indonesia continues to show progress. As the use of this technology in healthcare increases, aspects of quality, safety, and compliance with sharia principles are becoming crucial aspects that require attention. Responding to this need, ProSTEM is present as a stem cell and metabolite processing laboratory that is the first to receive a sharia compliance recommendation from LPPOM MUI for its autologous products .

This Sharia-compliant recommendation marks a significant milestone for ProSTEM in establishing standards for processing stem cell-based products and their metabolites. The assessment process not only examines the final product but also considers various aspects related to materials, processing, facilities, and the implementation of systems that support compliance with Sharia principles.

For patients and clinical partners, this achievement provides added value in terms of trust in the processing process and service quality . Stem cell and metabolite-based products require controlled processes and strict standards because they directly relate to patient therapeutic needs. By implementing structured processing standards, ProSTEM is committed to ensuring that each process is carried out consistently, documented, and meets established requirements.

More than just an administrative achievement, the sharia compliance recommendation from LPPOM MUI reflects ProSTEM's commitment to providing stem cell processing services that pay attention to quality, safety, process integrity, and the needs of the Indonesian people .

Amidst the development of regenerative therapies, trust is an integral aspect of innovation. ProSTEM strives to address this need by providing processing facilities that prioritize standards and accountable governance.

With this achievement, ProSTEM further strengthens its position as a facility supporting the development of stem cell and metabolite-based therapies in Indonesia. Maintained process quality and a commitment to safety standards are crucial in building trust among patients, physicians, and clinical partners.

Sumber: prostem.co.id